{"id":15487,"date":"2020-11-12T17:01:39","date_gmt":"2020-11-12T17:01:39","guid":{"rendered":"https:\/\/nclnet.org\/?p=15487"},"modified":"2020-11-17T16:04:08","modified_gmt":"2020-11-17T16:04:08","slug":"statement_covid_vaccine","status":"publish","type":"post","link":"https:\/\/nclnet.org\/statement_covid_vaccine\/","title":{"rendered":"NCL statement on vaccine for COVID-19"},"content":{"rendered":"<section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock  '   itemprop=\"text\" ><p>For immediate release: November 12, 2020<\/p>\n<p>Media contact: National Consumers League \u2013 Carol McKay, <a href=\"mailto:carolm@nclnet.org\">carolm@nclnet.org<\/a>, <a href=\"tel: +14129453242\">(412) 945-3242<\/a>\u00a0or Taun Sterling, <a href=\"mailto:tauns@nclnet.org\">tauns@nclnet.org<\/a>, <a href=\"tel: +12022072832\">(202)\u00a0207-2832<\/a><\/p>\n<p>Washington, DC \u2013The National Consumers League (NCL) welcomes the very hopeful news that a coronavirus vaccine with a reported efficacy rate of 90 percent may be approved and rolled out in the next few months. NCL has historically advocated for vaccines because they have overwhelming effectiveness and safety profiles, preventing billions of often debilitating and deadly diseases across the globe\u2014from small pox to measles to polio. The clinical evidence on the coronavirus vaccine\u2014developed by Pfizer Inc. and partner BioNTech SE\u2014though incomplete at the moment, is very promising.<\/p>\n<p>\u201cWe applaud the unprecedented cooperation by public and private entities, along with concerted coordination among scientists, doctors, and researchers that has gone into developing a vaccine to combat this terrible pandemic, which has killed over 237,000 Americans, struck 10 million people, and only shows signs of worsening over the winter months,\u201d said NCL Executive Director Sally Greenberg. \u201cAs this vaccine moves closer to being cleared for widespread use and the safety data verified, we are grateful to the companies and government officials who urgently prioritized the development of an effective and safe vaccine to combat the scourge of COVID-19. We are also encouraged that other companies are in the later stages of reviewing their own COVID-19 vaccines, which use different technologies to fight the virus but hopefully will be effective and safe as well.\u201d<\/p>\n<p>The FDA will be reviewing the safety data in the next few weeks on the Pfizer vaccine and will then determine to whom the first doses will be directed. Pfizer has said the vaccine could become available before the end of the year and that the company can produce 50 million doses globally\u2014equivalent to reaching 25 million people because two doses are required for maximum protection from the virus. The most vulnerable populations are likely to receive the first batch of vaccines.<\/p>\n<p>NCL cautioned consumers that during this period, people should maintain all the safety practices for preventing spread of the virus\u2014wearing masks and practicing social distancing and keeping social gatherings to a minimum.<\/p>\n<p>###<\/p>\n<p><strong>About the National Consumers League (NCL)<\/strong><\/p>\n<p>The National Consumers League, founded in 1899, is America\u2019s pioneer consumer organization. Our mission is to protect and promote social and economic justice for consumers and workers in the United States and abroad. For more information, visit www.nclnet.org.<\/p>\n<\/div><\/section>\n","protected":false},"excerpt":{"rendered":"<p>NCL welcomes the very hopeful news that a coronavirus vaccine with a reported efficacy rate of 90 percent may be approved and rolled out in the next few months. <\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_tribe_ticket_capacity":"0","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false},"categories":[290,416,16,292,294,291],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/nclnet.org\/wp-json\/wp\/v2\/posts\/15487"}],"collection":[{"href":"https:\/\/nclnet.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclnet.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclnet.org\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nclnet.org\/wp-json\/wp\/v2\/comments?post=15487"}],"version-history":[{"count":5,"href":"https:\/\/nclnet.org\/wp-json\/wp\/v2\/posts\/15487\/revisions"}],"predecessor-version":[{"id":15495,"href":"https:\/\/nclnet.org\/wp-json\/wp\/v2\/posts\/15487\/revisions\/15495"}],"wp:attachment":[{"href":"https:\/\/nclnet.org\/wp-json\/wp\/v2\/media?parent=15487"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclnet.org\/wp-json\/wp\/v2\/categories?post=15487"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclnet.org\/wp-json\/wp\/v2\/tags?post=15487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}